FATE News and Press, Fate Therapeutics Inc. From 01/06/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Layoffs have been making headlines so far in 2023, even though we’re just a few days into the new year. That’s true even for gene-editing stocks. While the focus has been on tech — and understandably so &...

Summary ImmunityBio, Inc. presented strong data from its lead asset in multiple indications. Lead indication has a May 23 PDUFA. I am not sure I understand how this company operates, in terms of money, I mean. ImmunityBio, Inc. ( IBRX ) is another Patrick Soon-Shiong c...

Fate Therapeutics ( NASDAQ: FATE ), which saw it shares plummet in after-hours trading Thursday, is facing a multitude of analyst downgrades after a collaboration agreement with Johnson & Johnson ( JNJ ) unit Janssen was ended. In early Friday afternoon trading, Fate ( F...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Fate Therapeutics (NASDAQ: FATE ) stock is falling hard on Friday after the company announced the termination of its collaboration with Janssen Biotech . Janssen was seek...

Investors in the Nasdaq Composite (NASDAQINDEX: ^IXIC) weren't too happy with their performance in 2022, and they hoped that the growth-heavy index would bounce back in 2023 from dramatically weaker returns than other major market benchmarks. Friday's early market moves only continued tha...

SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Fate Therapeutics, Inc. (NASDAQ: FATE) (“Fate” or the “Company), any of its executive officers, or others violated securities laws by misrepresenting o...

MONSEY, N.Y., Jan. 05, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Fate Therapeutics, Inc. (Nasdaq: FATE) (“FATE”) violated federal securities laws in connection with the sudden termination of its collaboration and option agreement with ...

Fate Therapeutics ( NASDAQ: FATE ) on Thursday said it had terminated its collaboration and option agreement with Johnson & Johnson's ( JNJ ) Janssen, with all collaboration activities set to be wound down in Q1 2023. As a result of the termination, FATE said it would prioriti...

Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization and Expense Reduction Advancing Second-generation CD19-targeted CAR NK Cell Program with Five Novel Synthetic Controls Designed to I...

Summary Shares have fallen by over 80% during the past 12 months. iPSC-derived NK cell programs sport advantages such as streamlined manufacturing, optimization and convenient administration. Solid tumor efforts and vast IP are two aspects of the story I feel are under-appreciated. ...